AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00586976 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline infusion at 4 ml/hour for 64 hours.
Study NCT01976143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NKTR-102
Study NCT04194814 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: crisaborole (2%) ointment
Description: twice daily application on one forearm for 4 weeks (randomised site allocation)
Study NCT04194814 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: betamethasone valerate 0.1% cream
Description: twice daily application on one forearm for 4 weeks (randomised site allocation)
Study NCT01020253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: alendronate, alfacalcidol
Description: Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
Study NCT01020253 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: alendronate, alfacalcidol
Description: Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
Study NCT01092663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam HCl
Description: Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
Study NCT01092663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
Study NCT03234491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DiAS
Description: Diabetes Assistant (DiAS) hybrid closed loop system.
Study NCT03234491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afrezza low dose
Description: Afrezza inhaled insulin low dose.
Study NCT03234491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Afrezza high dose
Description: Afrezza inhaled insulin high dose.
Study NCT01821482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic and Cytokine-induced Killer Cells
Study NCT03678168 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Throat Pack
Description: Post rhinology surgery throat packs will be used as a control to compare against the intervention (Pharyngeal tampons)
Study NCT03678168 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharyngeal Tampons
Description: Post rhinology surgery Pharyngeal Tampons will be used as an intervention to compare against the throat pack (control)
Study NCT01274429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peanut flour
Description: Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
Study NCT03565237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIXUBIS: On-Demand
Description: RIXUBIS used under standard clinical practice in India: On-Demand treatment.
Study NCT03565237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RIXUBIS: Prophylaxis
Description: RIXUBIS used under standard clinical practice in India: Prophylaxis treatment.
Study NCT04564872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 10 mg Q2W
Description: HSK7653 5 mg (2 tablets) and placebo 25 mg (1 tablet) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
Study NCT04564872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK7653 25 mg Q2W
Description: HSK7653 25 mg (1 tablet) and placebo 5 mg (2 tablets) Q2W, placebo of linagliptin 5 mg QD, oral, week 1 to week 24; HSK7653 25 mg (1 tablet) Q2W, oral, week 25 to week 52.
Study NCT04564872 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin 5 mg QD
Description: Linagliptin 5 mg QD, placebo of HSK7653 25 mg (1 tablet) and 5 mg (2 tablets) Q2W, oral, week 1 to week 24; HSK7653 25 mg Q2W, oral, week 25 to week 52.
Study NCT04506333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A&D UA-651 Blood Pressure Monitor
Description: Test device to be validated.
Study NCT02296307 — intervention group
Intervention type: OTHER
Intervention: Second Test: Transvaginal Ultrasound
Description: -Transvaginal Ultrasound at visit 1, day 1.
Study NCT02296307 — intervention group
Intervention type: OTHER
Intervention: Follow-up phone call
Description: Phone call 6 months after last visit to verify continued health.
Study NCT00936819 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Plasma-Lyte A and 25% Autologous Plasma
Description: Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
Study NCT00936819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EPCs
Description: Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
Study NCT00936819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous EPCs Transfected with human eNOS
Description: Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
Study NCT01318356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
Study NCT01318356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
Study NCT01318356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
Study NCT00668057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 5 mg Vardenafil orally 1 hour prior to sexual intercourse
Study NCT00668057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 10 mg Vardenafil orally 1 hour prior to sexual intercourse
Study NCT00668057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: 20 mg Vardenafil orally 1 hour prior to sexual intercourse
Study NCT00668057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mg matching placebo
Study NCT00668057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg matching placebo
Study NCT04374526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Convalescent Plasma
Description: ABO matched pathogen-inactivated CCP is transfused at a dose of 200 ml/day for 3 days (days 1, 2, and 3).
Study NCT01772017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tongue Advancement Retainer Device
Description: Tongue Advancement Retainer Device
Study NCT00668057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg matching placebo
Study NCT02074384 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Glucose Monitor
Description: CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
Study NCT02750436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided
Description: This group will be treated using an ultrasound imaging device
Study NCT02750436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy guided
Description: This group will be treated using a fluoroscopy imaging device
Study NCT02127931 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Groundskeeper for ADHD group
Description: Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
Study NCT02127931 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Groundskeeper for control group
Description: Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
Study NCT03117686 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: lung ultrasound
Description: lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro
Study NCT02723539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBN-101
Description: Topical application
Study NCT02723539 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application
Study NCT04084444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T8 tablet 0.5mg
Description: Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
Study NCT04084444 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T8 tablet 1mg
Description: Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
Study NCT04084444 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Blank control.
Study NCT02074384 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Self Monitoring Blood Glucose
Description: Participants will use their own SMBG device.
Study NCT02074384 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Clinician
Description: Survey of clinicians after study visits
Study NCT01934166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene 18 mg
Description: One single oral dose of 18 mg
Study NCT03958149 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: spinal collar
Description: cervical collar to immobilise the cervical spine
Study NCT03508206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SBRP
Description: SBRP capsules
Study NCT03508206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo capsules
Study NCT04085614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap
Description: Standard of care Percutaneous Coronary Intervention (PCI) with Dynamic Coronary Roadmap
Study NCT04085614 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
Description: Standard of care Percutaneous Coronary Intervention (PCI) without Dynamic Coronary Roadmap
Study NCT02680314 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
Study NCT03937752 — intervention group
Intervention type: OTHER
Intervention: 3D endodanal ultrasound
Description: Endoanal ultrasound performed with two different transducers preoperatively during a fistula treatment procedure.
Study NCT05533788 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABSK091 tablet
Description: ABSK091 tablet which is being developed for the treatment of patients with advanced solid tumors
Study NCT04759729 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Probiotic and vitamin D
Description: Participants enrolled to PRO + D group will receive probiotics and vitamin D supplements as a intervention product.~Participants enrolled to probiotic group will receive probiotics as well as vitamin D supplements.
Study NCT04759729 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: placebo and vitamin D
Description: Participants enrolled to PL+D group will receive vitamin D. Additionally they will get placebo instead of probiotics.
Study NCT03303131 — intervention group
Intervention type: OTHER
Intervention: Discharge from community-based management
Description: Comparison of patient characteristics and treatment outcomes between two groups
Study NCT04627389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orbicularis oris muscle Z- plasty modification of modified millard technique
Description: After orbicularis oris muscle had been released from the overlying skin, the previously marked points using methylene blue for designing the z-plasty were shown to be followed by back-cut incisions including the OOM and inner mucosa in both medial and lateral elements without involving the overlying skin. This procedure resulted in two triangular flaps in both segments
Study NCT05011604 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Full-Digital Workflow in Single-Tooth Implant Rehabilitation
Description: For all patients included in the study, a digital impression was taken using an intraoral scanner. A CBCT exam was performed on the mandibular or maxillary jaw with the missing tooth. The stl. and the dicom. files were then superimposed to allow the surgical planning.~Then it was elevated and reflected to increase the volume on the buccal side and exposed the bone surface. After this point, the implant was inserted, and another digital impression was taken.~Sutures 6.0 were positioned after healing abutment positioning to stabilize the soft tissues.~The final abutment and the provisional were designed and manufactured using cad-cam technology. One week thereafter, definitive abutment was positioned. Provisional restoration was then cemented using provisional cement removing all the possible occlusal contacts both in protrusive and in lateral positions. Three months thereafter, once osteointegration was obtained, definitive zirconia restoration was positioned and cemented.
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV, Days 1 of all cycles
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
Study NCT02064335 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity coaching
Description: Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Maintenance therapy.
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron
Description: Granisetron 1 mg IV on Day 1, Cycle 1 and 3
Study NCT00450801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron
Description: Decadron 10 mg IV on Day 1, Cycles 1 and 3
Study NCT03713229 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Screening for anal squamous intraepithelial lesions
Description: digital-anorectal exam, liquid-based cytology, human papillomavirus testing, high-resolution anoscopy
Study NCT02767037 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sudoscan and clinical assessment
Description: The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.
Study NCT02767037 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sudoscan and clinical assessment
Description: The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.
Study NCT02767037 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: Skin biopsy
Description: Evaluation of the denervation and synuclein deposition of skin biopsy
Study NCT02767037 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Skin biopsy
Description: Evaluation of the denervation and synuclein deposition of skin biopsy
Study NCT00750685 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Mentor Smooth Becker 50 Expander/Breast Implant
Description: The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
Study NCT04506333 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADC 740-N Manual Sphygmomanometer
Description: Reference device. Meets or exceeds ANSI/AAMI/ISO 81060-1 as required by ISO/ESH/AAMI standards.
Study NCT04627389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified millard technique
Description: no z-plasty modification
Study NCT00805194 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo plus docetaxel
Description: placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
Study NCT00805194 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120 plus docetaxel
Description: BIBF 1120 2 times daily along with standard therapy of docetaxel
Study NCT00958230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dCell Vascular Patch
Description: Implantation of a dCell Vascular Patch as part of an Endarterectomy
Study NCT01660503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 0 grams SCF
Description: Given in snack foods (muffins and flavored beverage)
Study NCT01660503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 grams SCF
Description: Given in snack foods (muffins and flavored beverage)
Study NCT01660503 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 grams SCF
Description: Given in snack foods (muffins and flavored beverage)
Study NCT00598325 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)
Description: 1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
Study NCT00771056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg by mouth daily x 1 year